The launch of the 750mcg teriparatide injection in Australia has seen controlled distribution to date. Primarily directed for patients with severe skeletal fragility who have not responded to other treatments , access is strictly managed. Current supply levels are constrained , and individuals should discuss from their physician the recent informat